Quick Takeaways: Why It Matters? The FDA’s Emergency Use Authorization for Simparica Trio to treat New World screwworm (NWS) larvae in dogs gives veterinarians a convenient, oral option that can be used alongside existing livestock tools (e.g., Dectomax...
Quick Takeaways: Why It Matters? By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital fo...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? CT-RevitL positions Enovis’s Companion Animal Health business to deepen its role in technology-enabled, non-drug pain and mobility management, giving clinics a more standardized, high-powered PBM platform that can turn laser therapy into a recurring, protoc...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? AKS-699 is being positioned as a long-interval, owner-friendly alternative to monthly IL‑31 biologics like Cytopoint in canine atopic dermatitis. The favorable efficacy and tolerability profile in preclinical work (only mild, transient injection-site r...
Quick Takeaways: Why It Matters? By adding a feline‑specific soft chew built on proprietary CBD + CBDA data, ElleVet deepens its position as a science‑led cannabinoid brand and expands use beyond dogs into a harder‑to‑treat cat population. The palatable, lo...
